Skip to content Skip to menu

Government support for ‘gene patents’ assures patient access to biological medicines

Friday, 25 November 2011

Media Release

The Federal Government’s support for the patenting of genetic materials should enable patients to continue enjoying access to biological medicines, the chief executive of Medicines Australia Dr Brendan Shaw said today.

Dr Shaw said the Government’s decision would benefit Australian patients as well as researchers and manufacturers of biological medicines.

“Patents on biological materials are important because they guarantee ongoing investment in developing cutting-edge medicines and therapies,” Dr Shaw said.

“They ensure Australians have access to these medicines as soon as they become available.

“Four Government inquiries over the last decade, including two by the Australian Senate, have found that there is no case for banning patients on biological materials.

“I congratulate the Government for recognising the value of patents of biological materials for the advancement of medicine.”

Medicines Australia supports the Government’s Raising the Bar Bill, which will bring Australia’s intellectual property system into line with intellectual property systems in other OECD countries.

“There is no doubt that Australia’s patent system needs to be reformed,” Dr Shaw said.

“The Government’s Raising the Bar Bill is the most effective mechanism for achieving those reforms.

The Raising the Bar Bill, currently before the Parliament, is more balanced and constructive than the proposed ban on gene patents,” Dr Shaw said.

“It will encourage medical innovators and research scientists and will better serve the Australian community at large.”


Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at